Related Experiment Video
Updated: Apr 20, 2026
09:04
Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus
Published on: March 28, 2025
879
Echinococcus metacestode: in search of viability markers
Bruno Gottstein1, Junhua Wang2, Oleg Blagosklonov3
1Institute of Parasitology, Vetsuisse Faculty and Faculty of Medicine, University of Bern, Switzerland.
Parasite (Paris, France)
|November 28, 2014
Summary
Accurate assessment of Echinococcus parasite viability is crucial for effective treatment. Current methods for alveolar echinococcosis (AE) and cystic echinococcosis (CE) lack validation, necessitating new diagnostic tools for better patient management and drug withdrawal decisions.
Area of Science:
- Parasitology
- Immunology
- Medical Diagnostics
Background:
- Most Echinococcus spp. infections are asymptomatic due to host resistance.
- Echinococcosis disease progression depends on host immunity, with impaired immunity leading to rapid metacestode proliferation.
- Current methods for assessing parasite viability in alveolar echinococcosis (AE) and cystic echinococcosis (CE) are limited.
Purpose of the Study:
- To review current and potential methods for assessing Echinococcus metacestode viability in vivo.
- To highlight the need for validated tools to guide therapeutic interventions and chemotherapy withdrawal.
- To identify areas for developing novel diagnostic markers for echinococcosis.
Main Methods:
- Review of existing literature on diagnostic techniques for echinococcosis viability assessment.
- Discussion of imaging modalities like FDG-PET and MRI.
- Exploration of serological markers (antibodies, antigens) and host-derived factors (cytokines, DNA).
Main Results:
- FDG-PET and recEm18 antibody measurement show promise for AE viability assessment but require further validation.
- Prognostic markers for Echinococcus granulosus are still lacking.
- Several candidate markers, including advanced MRI and molecular detection, show potential but lack clinical validation.
Conclusions:
- Reliable tools for assessing Echinococcus parasite viability are needed to optimize benzimidazole chemotherapy withdrawal.
- Further validation of existing methods and development of new biomarkers are essential for clinical application.
- Improved viability assessment will support the development of alternative therapeutic strategies for echinococcosis.
